Advertisement

Topics

Prefilled anti-VEGF injection may reduce risk of endophthalmitis

14:00 EDT 13 Mar 2018 | Healio

Philip Storey
PHILADELPHIA — Mounting evidence from an ongoing multicenter collaboration demonstrates that anti-VEGF injection via prefilled syringe may substantially reduce the risk of endophthalmitis compared with the conventional method of injection, Philip Storey, MD, MPH, said at the Wills Eye Conference.
Storey and colleagues conducted a retrospective case-control study of all patients with endophthalmitis at Wills Eye Hospital following a conventional vs. prefilled syringe method of delivering Lucentis (ranibizumab, Genentech) over a 2-year period. The incidence of endophthalmitis

Original Article: Prefilled anti-VEGF injection may reduce risk of endophthalmitis

NEXT ARTICLE

More From BioPortfolio on "Prefilled anti-VEGF injection may reduce risk of endophthalmitis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...